Ergoteles LLC Innoviva, Inc. Transaction History

Ergoteles LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$11.39 - $13.72 $366,758 - $441,784	32,200 New	32,200 $409,000
Q3 2022 Nov 14, 2022	BUY	$11.61 - $15.22 $206,216 - $270,337	17,762 New	17,762 $206,000
Q2 2022 Aug 12, 2022	SELL	$14.32 - $19.88 $222,962 - $309,531	-15,570 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$15.39 - $20.25 $239,622 - $315,292	15,570 New	15,570 $301,000
Q4 2021 Feb 14, 2022	SELL	$15.91 - $18.72 $1.53 Million - $1.8 Million	-96,400 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$13.06 - $17.24 $974,276 - $1.29 Million	74,600 Added 342.2%	96,400 $1.61 Million
Q2 2021 Aug 12, 2021	BUY	$11.45 - $13.96 $249,609 - $304,328	21,800 New	21,800 $292,000
Q4 2020 Feb 11, 2021	SELL	$9.33 - $12.48 $126,888 - $169,728	-13,600 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$10.33 - $14.49 $140,488 - $197,064	13,600 New	13,600 $142,000

229

79.2M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.33B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.